BioMarin Pharmaceutical Inc (BMRN) income statement
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30104% above fair value
$61.43+2.92 (+4.99%)
Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –
BioMarin Pharmaceutical Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 76.1%
- Operating margin
- 4.4%
- Net margin
- 2.1%
- Return on equity, FY2025
- 5.9%
Financial strength
- Current ratio
- 2.39
- Debt to equity
- 0.66
- Debt to assets
- 35.7%
- Cash to current liabilities
- 52.5%
Valuation
- P/E ratio
- 161.7
- Price to sales
- 3.49
- Price to book
- 1.88
- Dividend yield
- –
See a number that looks wrong?